argenx SE (EBR:ARGX)
Belgium flag Belgium · Delayed Price · Currency is EUR
492.00
+1.20 (0.24%)
Jul 18, 2025, 5:35 PM CET

argenx SE Company Description

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.

The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP).

It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, antibody-mediated rejection, and autoimmune encephalitis; empasiprubart for multifocal motor neuropath, CIDP, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome, amyotrophic lateral sclerosis, and spinal muscular atrophy.

In addition, the company is also developing ARGX-119, a MuSK agonist to treat congenital myasthenic syndromes and amyotrophic lateral sclerosis; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121 and ARGX 220 that targets the immune system; ARGX-213, which targets FcRn; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115.

It has strategic collaborations with OncoVerity, Inc, LEO Pharma A/S, Zai Lab Limited, AbbVie, Inc., Elektrofi, Genmab SE, Chugai Pharmaceutical Co., Ltd., Clayton Foundation, Halozyme Therapeutics, Inc., AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Lonza Sales AG, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, and IQVIA Ltd. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

argenx SE
argenx SE logo
CountryNetherlands
Founded2008
IndustryBiotechnology
SectorHealthcare
Employees1,599
CEOTimothy Van Hauwermeiren

Contact Details

Address:
Laarderhoogtweg 25
Amsterdam, 1101 EB
Netherlands
Phone31 10 703 8441
Websiteargenx.com

Stock Details

Ticker SymbolARGX
ExchangeEuronext Brussels
Fiscal YearJanuary - December
Reporting CurrencyUSD
ISIN NumberNL0010832176
SIC Code2836

Key Executives

NamePosition
Timothy Van Hauwermeiren EMBA, M.Sc.Co-Founder, Chief Executive Officer and Executive Director
Karl GubitzChief Financial Officer
Karen MasseyChief Operating Officer
Dr. Peter UlrichtsChief Scientific Officer
Malini MoorthyGeneral Counsel
Arjen Lemmen M.Sc.Vice President of Corporate Development and Strategy
Andria WilkGlobal Head of Quality
Dr. Luc TruyenChief Medical Officer
Filip BorgionsChief Technology Innovation Officer
Beth DelGiaccoVice President and Global Head of Corporate Communications and Investor Relations